Valeant Pharmaceuticals International News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.03.17	Biotechs Focus on Improving Cancer Pain Management for Enhanced Patient Care (PR Newswire)
22.03.17	Biotechs Focus on Improving Cancer Pain Management for Enhanced Patient Care (PR Newswire)
21.03.17	Valeant Completes Refinancing Transactions (PR Newswire)
21.03.17	PTIE Surges After-hours, Valeant Gets FDA Date, JAZZ Hits Right Notes (RTTNews)
21.03.17	Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018 (PR Newswire)
17.03.17	MÄRKTE USA/Anleger warten auf Impulse von G20 und Verfalltermin (Dow Jones)
14.03.17	MÄRKTE USA/Fallender Ölpreis zieht Aktienkurse abwärts (Dow Jones)
14.03.17	MÄRKTE USA/Fallende Ölpreise ziehen Aktien nach unten (Dow Jones)
14.03.17	MÄRKTE USA: Fallende Ölpreise ziehen Aktien nach unten (Dow Jones)
14.03.17	Ackman Sells Valeant Stake, To Step Down From Board (RTTNews)
10.03.17	Valeant Receives Lender Consent For Refinancing And Amendment Of Credit Agreement (PR Newswire)
10.03.17	Valeant Announces Upsizing Of Tender Offer For 6.75% Senior Notes Due 2018 (RTTNews)
10.03.17	Valeant Announces Pricing And Upsize Of Private Offering Of Senior Secured Notes (PR Newswire)
10.03.17	Valeant Announces Upsizing Of Cash Tender Offer For Its 6.75% Senior Notes Due 2018 (PR Newswire)
07.03.17	Valeant Commences Cash Tender Offer For Up To $600,000,000 Outstanding Principal Amount Of Its 6.75% Senior Notes Due 2018 (PR Newswire)
07.03.17	MÄRKTE USA/Konsolidierung geht weiter - Trump belastet Pharmawerte (Dow Jones)
06.03.17	InvestorsObserver releases covered-call reports for Apple, Advanced Micro Devices, NVIDIA, Twitter and Valeant Pharmaceuticals (PR Newswire)
06.03.17	Valeant Completes $1.1 Bln Pay Down Of Term Loans; To Seek Refinancing (RTTNews)
06.03.17	Valeant Completes Approximately $1.1 Billion Pay Down Of Senior Secured Term Loans From Divestitures; To Seek Refinancing And Amendment Of Credit Agreement (PR Newswire)
03.03.17	Valeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Oréal (PR Newswire)
02.03.17	Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation (PR Newswire)
01.03.17	Valeant Sales Drop; Plans To Relaunch 'Female Viagra' (RTTNews)
01.03.17	Gainers & Losers Of Feb.28: KITE, PBMD, LIFE, VRX, PRGO... (RTTNews)
28.02.17	Valeant Q4 Loss Widens (RTTNews)
27.02.17	Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity (PR Newswire)
27.02.17	Biotech Stocks Facing FDA Decision In March (RTTNews)
23.02.17	Research Reports Coverage on Healthcare Stocks -- Valeant Pharma, CVS Health, Express Scripts, and UnitedHealth (PR Newswire)
21.02.17	Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients (PR Newswire)
16.02.17	Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis (PR Newswire)
13.02.17	Valeant Pharmaceuticals To Participate At Healthcare Conferences (PR Newswire)
30.01.17	Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance (PR Newswire)
26.01.17	Options Trades for Alibaba, Salesforce, ArcelorMittal, Valeant Pharmaceuticals, and Verizon Communications Released by InvestorsObserver (PR Newswire)
18.01.17	First TV Spots For Kia Motors' All-New Niro Crossover On Air Now (PR Newswire)
13.01.17	Healthcare Stocks Under Scanner -- Valeant Pharma, Alkermes, Universal Health Services, and LifePoint Health (PR Newswire)
10.01.17	MÄRKTE USA/Nervöses Auf und Ab - Nur Nasdaq zeigt Stärke (Dow Jones)
10.01.17	MÄRKTE USA/Zurückhaltung vor Trump-Pressekonferenz (Dow Jones)
10.01.17	MÄRKTE USA/Zurückhaltung vor Trump-Pressekonferenz erwartet (Dow Jones)
10.01.17	MARKT USA/Zurückhaltung vor Trump-Auftritt erwartet (Dow Jones)
10.01.17	Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118 (PR Newswire)
10.01.17	L'Oréal kauft Hautpflegemarken von Valeant (AWP)
10.01.17	Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion (PR Newswire)
08.01.17	Fondsmanager Kubli: "Attraktiv bewertet sind Generika" (finanzen.ch)
04.01.17	Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors (PR Newswire)
12.12.16	Valeant Appoints William D. Humphries As EVP, Dermatology (PR Newswire)
08.12.16	Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118 (PR Newswire)
08.12.16	Pharming Announces Completion of Acquisition of All North American Commercialisation Rights for RUCONEST® From Valeant (PR Newswire)
07.12.16	Valeant Pharmaceuticals trade offers a 13.12% return in 226 days, or find similar option trades on Francesca's Holdings Company, Panera Bread Company, General Electric, and Intel (PR Newswire)
07.12.16	Pharming Announces Completion Of Financing for RUCONEST® North American Rights Acquisition (PR Newswire)
05.12.16	Research Reports Initiation on Healthcare Stocks -- Valeant Pharma, Akorn, Universal Health Services, and LifePoint Health (PR Newswire)
29.11.16	Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor® (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Valeant Pharmaceuticals International Inc.

Aktien Top/Flop

Meistgelesene Nachrichten